Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

bavituximab in combination with chemotherapy. The first bavituximab breast cancer trial is now underway and the two other trials are expected to begin soon. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from th
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 New Q4-2014 incentives help ... an industry leading unified communication and collaboration provider, ... to deliver cloud-based audio and web/video conferencing solutions ... With SoundConnect’s Q4 incentive partners will ... web conferencing licenses sold, now through December 31st, ...
(Date:10/27/2014)... HORSHAM, Pa. , Oct. 27, 2014 /PRNewswire/ ... Colitis Foundation of America (CCFA) announced today the ... , an educational campaign designed ... bowel diseases (IBD) on the paired role of ... To view the multimedia assets associated with ...
(Date:10/25/2014)... The report “Adipic Acid Market by Application, by ... & Forecast to 2019” report analyzes the adipic ... and trends in different regions. , Browse 119 ... 217 slides and in-depth TOC on “Adipic Acid ... http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers will receive 10% ...
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
Breaking Biology Technology:SoundConnect Unveils Q4 Partner Incentives 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... 21 ChemDiv Inc. and Avineuro,Pharmaceuticals Inc. ... and development,collaboration including formulation, safety and early ... psychiatric disorders. R&D services,will be provided by ... in Moscow. The new agreement provides for ...
... Queen,s University Belfast is to become the United Kingdom,s ... ,cyber-attacks, after a funding boost from the Engineering and ... the EPSRC will help fund a new Innovation and ... (CSIT) - which will be based at Queen,s Institute ...
... Nov. 20 Par Pharmaceutical Companies, Inc. (NYSE: ... Court for the District of New Jersey last night ... (TRO) halting sales of Teva,s generic Pulmicort Respules(R) (budesonide ... against Teva, AstraZeneca agreed and that it too would ...
Cached Biology Technology:ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia 2Queen's 'secures' £25m for UK's cyber-safety 2Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension 2
(Date:10/29/2014)... Genomics of the Kidney consortium ( CAGEKID ) ... exposure to aristolochic acid, an ingredient in some ... Communications , have important implications for public health. ... every year, and in Central Europe incidence rates ... International Cancer Genome Consortium (ICGC), has been studying ...
(Date:10/28/2014)... German . , ... food when times are lean? By studying wild chimpanzees ... of the Max Planck Institute for Evolutionary Anthropology in ... apes can acquire extra energy needed to maintain large, ... nests more en route to breakfast sites containing fruits ...
(Date:10/28/2014)... National University of Singapore (NUS) have discovered a new ... laying direct developing eggs in live bamboo with narrow ... bush frog ( Raorchestes chalazodes ). This critically ... known to adopt this novel reproductive strategy. The findings ... Biological Journal of the Linnean Society , in October ...
Breaking Biology News(10 mins):Kidney cancer in Central Europe 2The early chimp gets the fig 2The early chimp gets the fig 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3
... rise and more than 120 countries now in favor ... create a new, specialized global environmental agency, says one ... address to government ministers meeting Tuesday in Kenya, Zakri ... Malaysia and former co-chair of the UN Millennium Ecosystem ...
... Forum 2012 (ESOF 2012) was officially launched today at the ... Dublin this year from 11th to 15th July. ESOF 2012, ... in the heart of the Irish capital, in the new ... meeting, held under the auspices of Euroscience, which aims to ...
... winner-take-all competition in nature is an essential pillar of ... have about how, or whether, to teach the subject. ... and religion are in deliberate opposition, like two lionesses ... practicing Catholic Kenneth Miller teaches evolution, he also teaches ...
Cached Biology News:Create effective new global environmental agency, ministers urged 2Create effective new global environmental agency, ministers urged 3Science Program announced for Euroscience Open Forum 2012 in Dublin 2Science Program announced for Euroscience Open Forum 2012 in Dublin 3Science Program announced for Euroscience Open Forum 2012 in Dublin 4Science Program announced for Euroscience Open Forum 2012 in Dublin 5Teaching science to the religious? Focus on how theories develop 2Teaching science to the religious? Focus on how theories develop 3